Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smallpox vaccine stop mpox in its tracks?

NCT ID NCT05745987

Prevention Sponsor: McMaster University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether giving the smallpox vaccine to people who have been exposed to mpox can prevent them from getting sick or reduce the severity of the disease. It involves about 3,000 household members of people with confirmed mpox, who receive either the vaccine or a control. The study also looks at how the vaccine affects symptoms, skin lesions, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bavarian Nordic smallpox vaccine (Imvamune)
What this could lead to
If effective, this could provide a proven way to prevent mpox in people exposed to the virus, reducing spread and easing symptoms.
What could go wrong
The trial is still in progress, and results may not confirm the vaccine's effectiveness. There are also risks of allergic reactions, and the vaccine may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Household member of person with laboratory confirmed mpox 2. Age ≥ 2 years 3. Within 14 days of onset of illness in mpox index case Exclusion Criteria: 1. Pregnancy 2. Breastfeeding 3. Past serious allergic reaction to study vaccine components 4. Previous smallpox vaccination 5. Current or planned use of another investigational drug at any point during study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Monkeypox are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

monkeypox prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Monkeypox

Contacts and locations

Locations

  • Aminu Kano Teaching Hospital

    Kano, Nigeria

  • Catholic University of Bukavu

    Kinshasa, Bukavu, Democratic Republic of the Congo

  • Federal Medical Center

    Abuja, Nigeria

  • Irrua Specialist Teaching Hospital

    Irrua, Nigeria

  • Lagos University Teaching Hospital

    Lagos, Nigeria

  • Makerere University Lung Institute

    Kampala, Kampala, Uganda

  • Niger Delta Teaching Hospital

    Okolobiri, Nigeria

  • University of Abuja Teaching Hospital

    Abuja, Nigeria

  • University of Ibadan

    Ibadan, Nigeria

  • University of Port Harcourt Teaching Hospital

    Port Harcourt, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.